ArticleTherapeutic advances in medical oncology2026
Clinical and hematological indices as prognosticators in localized solitary fibrous tumors: A retrospective study.
Article in Therapeutic advances in medical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Solitary fibrous tumors (SFTs) are rare fibroblastic neoplasms for which prognostication is challenging. Peripheral hematological indices such as lymphocyte-monocyte ratio (LMR) and neutrophil-lymphocyte ratio (NLR) have demonstrated prognostic value in various malignancies but remain incompletely characterized in localized SFTs. Objectives: This study aimed to investigate clinicopathological factors and peripheral blood counts as predictors of survival outcomes in patients with SFT; and to explore their relationship with intratumoral gene expression profiles. Design: Retrospective cohort study. Methods: We analyzed patients with localized SFT managed at the National Cancer Centre Singapore (n = 77). Cut-offs for indices were derived from prior studies, and survival outcomes were analyzed using the Kaplan-Meier method and Cox proportional-hazards regression. Subgroup analysis with the NanoString PanCancer IO360 panel (n = 9) was done to explore associations between peripheral LMR and intratumoral immune-oncologic signals. Results: Median age at diagnosis was 55.7 years (range: 12.7 to 86.5 years) with a median follow-up time of 10.1 years. Low LMR (≤ 2.4) was observed in 14 patients (18.2%) and was significantly associated with poorer overall survival (OS) (HR 6.73, 95% CI 1.65 - 27.4, Conclusion: LMR may hold prognostic value for SFTs, though further validation in larger, multi-institutional cohorts is warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.